Chamberlain reads the guardian. Wouldn’t have guessed. :) Can’t see shareholders agreeing to anything this BOD suggests so it looks like we’ll be wound up. How much can we get through before then I wonder?
Not only has the price action been excellent this year but the last week has been very reassuring. The potential of this company is significant and the message appears to be getting out that it is in robust health, well managed with a great future. I think the team are doing a very good job. Exciting times.
Lots of viruses give you equivalent immunity. The point is, can you afford the risk of getting the original infection? Look at the viruses we routinely vaccinate ourselves against from childhood.
RE: RNS. Another £multi million RSV contract!9 Feb 2023 09:20
It doesn’t sound like I’m the one who is emotionally attached to this share! I’m also not the one who expected Rome to be built in a day. Based on fundamentals I have added as the share price declined, my final top up at just over 9p around Xmas. Happy to let the businessmen and the scientists deliver value for me. If they don’t I’ll blame myself not others.
RE: Let’s Start by Getting a 2 in Front7 Feb 2023 13:27
Look at everything that has happened since then. Management strengthened, repeat business from top pharma clients, new markets opened, strong balance sheet etc etc. Deserves to be much higher.
I think the update and presentation was a turning point in terms of not selling into good news, this last contract win plus weekend tipping has cemented the upbeat feeling.
RE: RNS. Another £multi million RSV contract!6 Feb 2023 09:38
Happy that we are locking in a person who has clearly demonstrated the ability to enhance share value for me as a shareholder. Delighted with another APAC win. A good day!
Really is getting pathetic when silly stories like this are used to distract from an excellent update and presentation. I hear there’s a green comet coming next week, surely this will negatively impact on the £76m+ nailed on for next year.
Confirmation, if any was required, that Hvivo is not a leaky ship when it comes to RNS’s. An excellent set of results that reflects admirably on the team. Exceeded expectations and that dividend carrot is bound to prick the ears of the wider investment community.